Troy A. Ignelzi's Net Worth
$24.1 Million
Who is Troy A. Ignelzi?
Troy A. Ignelzi has an estimated net worth of $24.1 Million. This is based on reported shares across multiple companies, which include Karuna Therapeutics, Inc., Esperion Therapeutics, Inc., , scPharmaceuticals Inc., Contineum Therapeutics, Inc., and Rapport Therapeutics, Inc..
SEC CIK
Troy A. Ignelzi's CIK is 0001579829
Past Insider Trading and Trends
2021 was Troy A. Ignelzi's most active year for acquiring shares with 16 total transactions. Troy A. Ignelzi's most active month to acquire stocks was the month of January. 2020 was Troy A. Ignelzi's most active year for disposing of shares, totalling 28 transactions. Troy A. Ignelzi's most active month to dispose stocks was the month of August. 2022 saw Troy A. Ignelzi paying a total of $465,621.20 for 99,111 shares, this is the most they've acquired in one year. In 2022 Troy A. Ignelzi cashed out on 104,355 shares for a total of $11,653,532.91, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Karuna Therapeutics, Inc. (KRTX) No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$92.16 | -$248,882.55 | 30.49K |
Aug 22
| |||
Form 4
|
—
|
0
|
$116.31 | -$1,927,861.67 | 30.49K |
May 23
| |||
Form 4
|
—
|
0
|
$99.60 | -$1,084,860.00 | 30.49K |
Scheduled
|
Feb 21
| ||
Form 4
| +39.61% | 8.65K |
—
|
—
| 30.49K |
Feb 9
| |||
Form 4
|
—
|
0
|
$105.18 | -$195,223.57 | 21.84K |
Scheduled
|
Jan 17 - Jan 18
| ||
Form 4
| +119.03% | 11.87K |
$9.20 | $109,176.40 | 21.84K |
Dec 16
| |||
Form 4
|
—
|
0
|
$117.53 | -$3,574,725.00 | 9.97K |
Scheduled
|
Nov 15
| ||
Form 4
| -60.07% | -15.00K |
$229.61 | -$3,444,116.71 | 9.97K |
Sep 30 - Oct 4
| |||
Form 4
|
—
|
0
|
$118.52 | -$3,607,395.00 | 24.97K |
Scheduled
|
Aug 9
| ||
Form 4
|
—
|
0
|
$70.22 | -$517,941.40 | 24.97K |
Scheduled
|
Apr 19 - Apr 21
| ||
Form 4
|
—
|
0
|
$60.17 | -$152,910.00 | 24.97K |
Scheduled
|
Feb 15 - Feb 16
| ||
Form 4
| +38.72% | 6.97K |
$9.20 | $64,124.00 | 24.97K |
Dec 21
| |||
Form 4
|
—
|
0
|
$80.76 | -$1,932,120.00 | 18K |
Scheduled
|
Nov 8
| ||
Form 4
|
—
|
0
|
$63.29 | -$1,081,846.00 | 18K |
Scheduled
|
Sep 8 - Sep 10
| ||
Form 4
| +38.46% | 5K |
$9.20 | $46,000.00 | 18K |
Aug 20
| |||
Form 4
|
—
|
0
|
$69.66 | -$423,268.40 | 13K |
Jun 14 - Jun 16
| |||
Form 4
|
—
|
0
|
$59.78 | -$728,250.00 | 13K |
Scheduled
|
May 10 - May 12
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 23
| |||
Form 4
|
—
|
0
|
$64.38 | -$1,103,700.00 | 13K |
Scheduled
|
Feb 16
| ||
Form 4
|
—
|
0
|
$56.85 | -$762,320.00 | 13K |
Scheduled
|
Jan 8
| ||
Form 4
| +160.00% | 8K |
$9.20 | $73,600.00 | 13K |
Dec 29
| |||
Form 4
|
—
|
0
|
$57.41 | -$964,053.92 | 5K |
Scheduled
|
Nov 6 - Nov 10
| ||
Form 4
|
—
|
0
|
$41.25 | -$128,200.00 | 5K |
Scheduled
|
Sep 8
| ||
Form 4
|
∞
| 5K |
$9.20 | $46,000.00 | 5K |
Aug 25
| |||
Form 4
|
—
|
0
|
$53.97 | -$716,320.00 |
0
|
Scheduled
|
Jul 8
| ||
Form 4
|
—
|
0
|
$50.76 | -$664,880.00 |
0
|
Scheduled
|
Jun 15 - Jun 16
| ||
Form 4
|
—
|
0
|
$46.29 | -$556,350.00 |
0
|
Scheduled
|
May 8
| ||
Form 4
|
—
|
0
|
$47.85 | -$579,750.00 |
0
|
Scheduled
|
Mar 2
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Esperion Therapeutics, Inc. (ESPR) Snapshot price: $1.69
Vice President
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
scPharmaceuticals Inc. (SCPH) Snapshot price: $5.3
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Contineum Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
| No matching records found | |||||||||